Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAtla, Inc. stock logo
BCAB
BioAtla
$0.39
+0.5%
$0.43
$0.24
$2.53
$22.67M0.91913,306 shs485,663 shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$34.25
+2.7%
$33.12
$29.31
$61.38
$4.09B0.591.52 million shs1.49 million shs
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$92.02
-1.0%
$107.10
$87.80
$155.12
$502.43M0.8655,032 shs125,669 shs
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$17.59
$17.67
$9.93
$32.94
$818.60M1.454,965 shsN/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAtla, Inc. stock logo
BCAB
BioAtla
+1.58%-2.53%-19.90%+44.73%-70.76%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-1.59%+0.97%+3.28%-3.50%-39.90%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-9.25%-1.36%-10.63%-11.69%+1.60%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioAtla, Inc. stock logo
BCAB
BioAtla
2.715 of 5 stars
3.32.00.00.03.12.50.6
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.8834 of 5 stars
4.52.00.04.60.00.80.0
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
3.0414 of 5 stars
3.03.00.80.01.92.51.3
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAtla, Inc. stock logo
BCAB
BioAtla
2.50
Moderate Buy$5.001,188.33% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.93
Moderate Buy$70.92107.07% Upside
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
2.00
Hold$130.0041.27% Upside
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BCAB, MLAB, ZEAL, and CYTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.00
5/30/2025
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$120.00 ➝ $100.00
5/29/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.00
5/14/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
5/13/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/8/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.00
5/7/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$86.00 ➝ $80.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$47.00 ➝ $41.00
5/2/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00 ➝ $72.00
4/24/2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$55.00
(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAtla, Inc. stock logo
BCAB
BioAtla
$11M2.06N/AN/A$0.25 per share1.55
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$18.47M221.47N/AN/A($1.15) per share-29.78
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$240.98M2.08$10.92 per share8.43$29.42 per share3.13
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
$46.54M17.59N/AN/A$3.38 per share5.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAtla, Inc. stock logo
BCAB
BioAtla
-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
-$1.97M-$0.37N/A10.55N/A-0.82%27.51%9.78%8/4/2025 (Estimated)
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
-$161.99M-$4.09N/AN/AN/A-565.44%-111.04%-56.54%N/A

Latest BCAB, MLAB, ZEAL, and CYTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/4/2025Q1 2026
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$2.46N/AN/AN/A$60.45 millionN/A
5/6/2025Q1 2025
BioAtla, Inc. stock logo
BCAB
BioAtla
-$0.28-$0.29-$0.01-$0.26N/AN/A
5/6/2025Q1 2025
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
$0.640.70%N/AN/A N/A
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
N/AN/AN/AN/AN/A

Latest BCAB, MLAB, ZEAL, and CYTK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/7/2025
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
quarterly$0.160.7%8/29/20258/29/20259/15/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
2.35
2.35
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
5.99
5.99
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
0.48
0.63
0.47
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
0.93
4.79
4.78

Institutional Ownership

CompanyInstitutional Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
90.60%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
1.73%

Insider Ownership

CompanyInsider Ownership
BioAtla, Inc. stock logo
BCAB
BioAtla
11.50%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
4.40%
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
2.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAtla, Inc. stock logo
BCAB
BioAtla
6058.42 million51.70 millionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250119.43 million115.37 millionOptionable
Mesa Laboratories, Inc. stock logo
MLAB
Mesa Laboratories
6805.46 million5.22 millionNot Optionable
Zealand Pharma A/S stock logo
ZEAL
Zealand Pharma A/S
35546.54 million45.51 millionNot Optionable

Recent News About These Companies

Zealand Pharma Appoints Chief Development Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAtla stock logo

BioAtla NASDAQ:BCAB

$0.39 +0.00 (+0.54%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 +0.00 (+0.75%)
As of 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$34.25 +0.89 (+2.67%)
Closing price 04:00 PM Eastern
Extended Trading
$33.64 -0.61 (-1.78%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Mesa Laboratories stock logo

Mesa Laboratories NASDAQ:MLAB

$92.02 -0.92 (-0.99%)
As of 04:00 PM Eastern

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Zealand Pharma A/S stock logo

Zealand Pharma A/S NASDAQ:ZEAL

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.